Our PDA®-derived XPro® technology is shaping clinical performance of protein therapeutic drugs by engineering important features such as solubility, expression, formulation, stability, shelf-life, and pharmacokinetics. Because we can also engineer the affinity and specificity of protein-protein interactions, we are also generating entirely new therapeutic mechanisms of action. Our strategy is to define the product specification necessary for a successful drug candidate and they apply XPro® technology to engineer the protein’s amino acid sequence to meet the specification.
We have applied our XPro® technology to the development of XPro®1595. It has a novel Dominant Negative mechanism of action that is designed to significantly impact the treatment of rheumatoid arthritis and other disease by offering much more selective inhibition of TNFα than is currently possible. We also used XPro® technology to greatly increase the half-life of the molecule via PEGylation and to provide high-level expression. XPro®1595 and other Xencor protein therapeutics are the first of a new generation of protein therapeutic drugs made possible with XPro® technology.
We are also developing protein variants for major partners to improve their physical and biological properties in an effort to improve their potential to treat disease. These collaborations leverage the unique capability of our XPro® technology to control amino acid sequence for the improvement of complex biophysical traits.